Valuation: Relay Therapeutics, Inc.

Market Cap 4.04B 3.55B 3.27B 3.06B 5.74B 382B 5.86B 39.29B 15.2B 189B 15.19B 14.86B 654B P/E 2026 *
-12.1x
P/E 2027 * -11.8x
Enterprise Value 3.75B 3.29B 3.03B 2.84B 5.32B 354B 5.44B 36.46B 14.11B 175B 14.09B 13.78B 607B EV / Sales 2026 *
299x
EV / Sales 2027 * 234x
Free-Float
93.62%
Yield 2026 *
-
Yield 2027 * -
1 day+4.09%
1 week+16.88%
Current month+32.10%
1 month+33.53%
3 months+93.33%
6 months+116.82%
Current year+119.39%
1 week 16.64
Extreme 16.645
18.94
1 month 12.92
Extreme 12.925
18.94
Current year 7.01
Extreme 7.01
18.94
1 year 3.02
Extreme 3.025
18.94
3 years 1.78
Extreme 1.775
18.94
5 years 1.78
Extreme 1.775
38.6
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 2017-02-28
Director of Finance/CFO 49 2018-03-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 2015-05-03
Director/Board Member 66 2016-06-30
Director/Board Member 52 2017-02-28
Date Insider Type Main position Quantity % Market Cap.
06-21Fiscal year

Chief Technology Officer

280,368 0.1463%
06-21Sell

Chief Financial Officer

-526,055 0.2746%
06-08Free

Director

32,947 0.0172%
Change 5-day change 1-year change 3-year change Capi.($)
+4.09%+16.88%+462.42%+41.25% 4.04B
+0.32%+7.27%-4.99%+2.64% 46.2B
+2.19%+11.71%+393.31%+580.42% 38.71B
+2.53%+13.93%+21.38%-12.81% 31.9B
+1.65%+3.61%+16.04%+55.62% 31.12B
-4.16%-2.58%+8.94%+25.31% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+130.07% 15.05B
-1.39%+7.12%+12.51%+20.35% 13.74B
+3.63%+9.53%+103.97%+98.73% 13.42B
Average +1.14%+9.91%+120.36%+104.62% 23.42B
Weighted average by Cap. +1.02%+8.85%+95.77%+129.58%

Financials

2026 *2027 *
Net sales 12.55M 11.01M 10.15M 9.5M 17.81M 1.18B 18.18M 122M 47.19M 585M 47.14M 46.11M 2.03B 16.32M 14.31M 13.19M 12.35M 23.16M 1.54B 23.64M 159M 61.35M 761M 61.29M 59.95M 2.64B
Net income -288M -253M -233M -218M -409M -27.19B -417M -2.8B -1.08B -13.44B -1.08B -1.06B -46.6B -303M -266M -245M -230M -431M -28.62B -439M -2.95B -1.14B -14.15B -1.14B -1.11B -49.05B
Net Debt -292M -256M -236M -221M -414M -27.55B -423M -2.84B -1.1B -13.61B -1.1B -1.07B -47.21B -221M -194M -179M -167M -313M -20.83B -320M -2.15B -830M -10.3B -829M -811M -35.71B
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
193
Date Price Change Volume
26-06-26 US$18.56 +4.09% 12,573,933
26-06-25 US$17.83 -1.05% 7,190,474
26-06-24 US$18.02 +3.33% 4,596,966
26-06-23 US$17.44 +0.93% 5,390,191
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
18.56USD
Average target price
24.82USD
Spread / Average Target
+33.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLAY Stock